Market closed
Skye Bioscience, Inc./$SKYE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Skye Bioscience, Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Ticker
$SKYE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
16
Website
SKYE Metrics
BasicAdvanced
$62M
-
-$0.73
1.89
-
Price and volume
Market cap
$62M
Beta
1.89
52-week high
$3.73
52-week low
$1.14
Average daily volume
1.2M
Financial strength
Current ratio
16.324
Quick ratio
15.771
Long term debt to equity
0.401
Total debt to equity
0.668
Interest coverage (TTM)
-40.30%
Management effectiveness
Return on assets (TTM)
-44.56%
Return on equity (TTM)
-80.48%
Valuation
Price to book
0.9
Price to tangible book (TTM)
0.9
Price to free cash flow (TTM)
-2.8
Growth
Earnings per share change (TTM)
-86.41%
3-year earnings per share growth (CAGR)
-48.16%
SKYE News
AllArticlesVideos
Skye Bioscience to Participate in May Investment and Medical Conferences
GlobeNewsWire·1 week ago
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value
Seeking Alpha·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Skye Bioscience, Inc. stock?
Skye Bioscience, Inc. (SKYE) has a market cap of $62M as of May 07, 2025.
What is the P/E ratio for Skye Bioscience, Inc. stock?
The price to earnings (P/E) ratio for Skye Bioscience, Inc. (SKYE) stock is 0 as of May 07, 2025.
Does Skye Bioscience, Inc. stock pay dividends?
No, Skye Bioscience, Inc. (SKYE) stock does not pay dividends to its shareholders as of May 07, 2025.
When is the next Skye Bioscience, Inc. dividend payment date?
Skye Bioscience, Inc. (SKYE) stock does not pay dividends to its shareholders.
What is the beta indicator for Skye Bioscience, Inc.?
Skye Bioscience, Inc. (SKYE) has a beta rating of 1.89. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.